About Careers MedBlog Contact us

Sarilumab Shows Promise in Slowing Down Joint Destruction in RA

by Kathy Jones on November 25, 2013 at 9:03 PM
Font : A-A+

 Sarilumab Shows Promise in Slowing Down Joint Destruction in RA

A new study is reporting that a new drug called sarilumab may be able to ease symptoms and slow down joint destruction in rheumatoid arthritis (RA).

The year-long study involved 1,200 patients with active, moderate-to-severe rheumatoid arthritis. All patients had either not benefitted from currently available treatments or had not been able to tolerate them.


Patients who received a 200 mg dose of Sarilumab every alternate week along with methotrexate experienced a 66 percent improvement in the symptoms of rheumatoid arthritis after six months. Patients who received a 150 mg dose of the new drug experienced a 58 percent reduction in symptoms like pain and swelling.

"The initial results from this trial look quite promising in terms of reducing painful symptoms," a spokesman for Arthritis Research UK told The Daily Mail. "Sarilumab is still under development and results of this study have not yet been published."

Sarilumab has been developed by Sanofi and Regeneron.

Source: Medindia


Recommended Reading

Latest Clinical Trials News

How Targeted Therapy Achieves Responses Across Multiple Cancer Types?
Erdafitinib is the first approved FGFR-targeted treatment for advanced urothelial cancer, reveal scientists.
Parkinson's Disease Drug Ropinirole Slows Progression of ALS
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
 Nanorobots: A Revolutionary Tool in Targeting Fungal Infections
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
 Gene Therapy Using Adeno Virus Reverses Age-Related Hearing Loss
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
Stickers Promise a Painless Mode of Measles Vaccine Delivery
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Sarilumab Shows Promise in Slowing Down Joint Destruction in RA Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests